Merck
HomeWebinarsPayload Core Product Line Accelerates ADC Clinical Timelines

Payload Core Product Line Accelerates ADC Clinical Timelines



WEBINAR

Dolastatins are antimitotic peptides that exhibit highly potent cytotoxic effects in cancer cells. Due to their pronounced antitumor effects, dolastatins have demonstrated clinical success as payloads for ADCs. However, innovators still face numerous challenges when developing and manufacturing ADC therapies, leading to increased costs and delayed timelines. Our core product line aims to address these challenges.

DOLCore™ product is a versatile and advanced intermediate that can simplify the synthesis of dolastatin payloads by reducing the number of synthesis steps from 15-20 to four or fewer. The value of DOLCore™ translates to significant savings in development and manufacturing costs driven by risk reduction in payload synthesis and avoidance of supply chain disruption.

In this webinar, you will learn about:

  • The advantages of dolastatin over other payloads in ADC therapies
  • Proprietary DOLCore™ and MayCore™ products
  • Flexibility to make new or established dolastatins
  • Rapid synthesis technology accelerating the path to drug commercialization
  • Seamless supply chain with reduced complexity and regulatory support

Speaker

David Goeddel, Ph.D.

David Goeddel, Ph.D.

Merck

Director of API R&D

David leads a team responsible for introducing new API products and implementing new technologies inside of actives and formulations R&D. Prior to this role, David was a manager and process chemist specializing in API process development. David earned a Ph.D. in Chemistry from Colorado State where he studied under advisors, Yian Shi and Albert Meyers.

Webinar Information

Pharma and biopharma manufacturing

  • Antibody drug conjugate manufacturing
  • Duration:51min

  • Language:English

  • Presented:Thu, December 2, 2021

    Watch Now